Jump to content

Gomiliximab

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by CheMoBot (talk | contribs) at 02:59, 25 October 2016 (Updating {{infobox_drug}} (changes to verified fields - updated 'ChemSpiderID_Ref') per Chem/infobox_drug validation (report errors or bugs)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Gomiliximab
Monoclonal antibody
TypeWhole antibody
SourceChimeric (primate/human)
TargetCD23
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
 ☒NcheckY (what is this?)  (verify)

Gomiliximab is a monoclonal antibody acting as an immunosuppressive drug for the treatment of allergic asthma. It targets the low affinity IgE receptor (FcεRII or CD23).[1] The drug is a chimeric antibody from Macaca irus and Homo sapiens.[1]

This drug was developed by IDEC Pharmaceuticals Corporation.

References

  1. ^ a b Statement On A Nonproprietary Name Adopted By The Usan Council - Gomiliximab, American Medical Association.


Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Gomiliximab&oldid=746070541"